GlaxoSmithKline Pharmaceuticals Limited
NSE: GLAXO BSE: GLAXO
Prev Close
3150.2
Open Price
3150.8
Volume
96,877
Today Low / High
3150.2 / 3200
52 WK Low / High
1921 / 3515.7
Range
3,037 - 3,357
Prev Close
3144.35
Open Price
3145.05
Volume
1,224
Today Low / High
3145.05 / 3200.35
52 WK Low / High
1924.3 / 3515.95
Range
3,035 - 3,354
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 3197 (target range: 3,037 - 3,357), reflecting a change of 46.8 (1.48562%). On the BSE, it is listed at 3194.7 (target range: 3,035 - 3,354), showing a change of 50.35 (1.60128%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
GlaxoSmithKline Pharmaceuticals Limited Graph
GlaxoSmithKline Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for GlaxoSmithKline Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 3,197.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 3,194.70 | 3,226.65 | 2,903.98 - 3,549.31 |
| 3,258.59 | 2,606.88 - 3,910.31 | ||
| 3,290.54 | 2,303.38 - 4,277.70 | ||
| Bearish Scenario | 3,194.70 | 3,162.75 | 2,846.48 - 3,479.03 |
| 3,130.81 | 2,504.64 - 3,756.97 | ||
| 3,098.86 | 2,169.20 - 4,028.52 |
Overview of GlaxoSmithKline Pharmaceuticals Limited
ISIN
INE159A01016
Industry
Drug Manufacturers - General
Vol.Avg
166,977
Market Cap
541,590,982,000
Last Dividend
54
Official Website
IPO Date
2002-07-01
DCF Diff
-2,566.63
DCF
5,764
Financial Ratios Every Investor Needs
Stock Dividend of GLAXO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-05-30 | May 30, 25 | 42 | 42 | 2025-05-30 | 2025-07-27 | |
| 2024-11-07 | November 07, 24 | 12 | 12 | 2024-11-07 | 2024-11-28 | |
| 2024-05-31 | May 31, 24 | 32 | 32 | 2024-05-31 | 2024-07-28 | |
| 2023-06-30 | June 30, 23 | 32 | 32 | 2023-06-30 | 2023-08-25 | |
| 2022-07-07 | July 07, 22 | 90 | 90 | 2022-07-08 | 2022-08-25 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,749.21 Cr | 1,390.86 Cr | 2,358.35 Cr | 0.6290 | 0.00 Cr | 0.00 Cr | 1,778.65 Cr | 927.58 Cr | 54.76 | 1,177.36 Cr | 0.2474 |
| 2024-03-31 | 3,441.77 Cr | 1,419.85 Cr | 2,021.92 Cr | 0.5875 | 2.54 Cr | 48.63 Cr | 1,360.20 Cr | 589.96 Cr | 34.83 | 887.30 Cr | 0.1714 |
| 2023-03-31 | 3,251.72 Cr | 1,284.87 Cr | 1,966.85 Cr | 0.6049 | 1.91 Cr | 29.19 Cr | 839.18 Cr | 610.69 Cr | 36.05 | 903.42 Cr | 0.1878 |
| 2022-03-31 | 3,278.03 Cr | 1,449.65 Cr | 1,828.38 Cr | 0.5578 | 1.83 Cr | 42.59 Cr | 769.14 Cr | 380.77 Cr | 22.48 | 848.83 Cr | 0.1162 |
| 2021-03-31 | 3,198.86 Cr | 1,394.67 Cr | 1,804.19 Cr | 0.5640 | 1.81 Cr | 18.47 Cr | 761.49 Cr | 358.15 Cr | 21.14 | 535.63 Cr | 0.1120 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,403.52 Cr | 4,108.08 Cr | 2,156.77 Cr | 1,951.3100 Cr | 9.95 Cr | -1,393.57 Cr | 481.74 Cr | 283.86 Cr | 0.00 Cr | 0.00 Cr | 12.28 Cr | 1,905.1700 Cr |
| 2024-03-31 | 64.17 Cr | 3,556.62 Cr | 1,778.98 Cr | 1,777.6397 Cr | 18.67 Cr | -45.51 Cr | 525.05 Cr | 310.73 Cr | 7.55 Cr | 0.00 Cr | 3.42 Cr | 1,524.9461 Cr |
| 2023-03-31 | 34.94 Cr | 3,326.58 Cr | 1,585.30 Cr | 1,741.2800 Cr | 15.54 Cr | -19.40 Cr | 459.97 Cr | 315.12 Cr | 830.29 Cr | -18.20 Cr | -1,764.82 Cr | 1,326.3600 Cr |
| 2022-03-31 | 286.19 Cr | 4,633.28 Cr | 1,970.32 Cr | 2,662.9558 Cr | 20.08 Cr | -266.11 Cr | 534.70 Cr | 325.45 Cr | 4.35 Cr | -18.89 Cr | -2,624.70 Cr | 1,698.4288 Cr |
| 2021-03-31 | 405.19 Cr | 3,113.36 Cr | 1,614.28 Cr | 1,499.0797 Cr | 34.63 Cr | -370.56 Cr | 546.70 Cr | 354.12 Cr | 836.63 Cr | -15.57 Cr | -728.00 Cr | 1,332.4743 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,289.9100 Cr | -45.8100 Cr | -769.4200 Cr | 1,266.8900 Cr | 474.6788 Cr | 538.8500 Cr | -23.0200 Cr | 927.5800 Cr | -18.7300 Cr | -749.3800 Cr | 43.3100 Cr |
| 2024-03-31 | 582.0155 Cr | -84.7206 Cr | -561.4969 Cr | 550.7940 Cr | 29.2303 Cr | 64.1712 Cr | -31.2215 Cr | 589.9610 Cr | -18.1253 Cr | -541.5729 Cr | -65.0778 Cr |
| 2023-03-31 | 484.2300 Cr | 807.8500 Cr | -1,543.3300 Cr | 440.1900 Cr | -251.2500 Cr | 34.9400 Cr | -44.0400 Cr | 841.5000 Cr | 0.0000 Cr | -1,525.4999 Cr | 74.7200 Cr |
| 2022-03-31 | 810.7478 Cr | -405.5076 Cr | -524.2423 Cr | 776.1068 Cr | -119.0021 Cr | 286.1871 Cr | -34.6410 Cr | 2,475.6481 Cr | -0.0240 Cr | -506.6350 Cr | 12.0027 Cr |
| 2021-03-31 | 577.9254 Cr | 418.5916 Cr | -696.1393 Cr | 533.6988 Cr | 300.3777 Cr | 405.1892 Cr | -44.2266 Cr | 723.0952 Cr | -0.1530 Cr | -677.0443 Cr | -46.7930 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 974.37 Cr | 351.94 Cr | 622.43 Cr | 0.6388 | 318.47 Cr | 262.87 Cr | 15.52 | 335.17 Cr | 0.2698 |
| 2024-12-31 | 949.42 Cr | 359.16 Cr | 590.26 Cr | 0.6217 | 273.12 Cr | 229.88 Cr | 13.57 | 326.99 Cr | 0.2421 |
| 2024-09-30 | 1,010.77 Cr | 552.06 Cr | 458.71 Cr | 0.4538 | 304.85 Cr | 252.50 Cr | 14.91 | 360.94 Cr | 0.2498 |
| 2024-06-30 | 814.65 Cr | 462.96 Cr | 351.69 Cr | 0.4317 | 214.13 Cr | 182.33 Cr | 10.76 | 230.54 Cr | 0.2238 |
| 2024-03-31 | 929.80 Cr | 558.06 Cr | 371.74 Cr | 0.3998 | 239.16 Cr | 194.48 Cr | 11.48 | 289.49 Cr | 0.2092 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,403.52 Cr | 1,118.25 Cr | 2,521.77 Cr | 292.55 Cr | 481.74 Cr | 3,409.89 Cr | 283.86 Cr | 4,108.08 Cr | 2,156.77 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,110.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,672.69 Cr |
| 2024-09-30 | 49.26 Cr | 1,000.82 Cr | 2,110.83 Cr | 268.36 Cr | 517.62 Cr | 3,014.35 Cr | 297.64 Cr | 3,745.99 Cr | 2,073.30 Cr |
| 2024-06-30 | -1,856.82 Cr | 3,713.65 Cr | 1,856.82 Cr | 0.00 Cr | 0.00 Cr | 1,856.82 Cr | 0.00 Cr | 0.00 Cr | -1,777.64 Cr |
| 2024-03-31 | 86.08 Cr | 1,792.65 Cr | 1,878.73 Cr | 222.06 Cr | 533.91 Cr | 2,798.42 Cr | 312.26 Cr | 3,573.75 Cr | 1,796.11 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 262.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 229.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 252.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 182.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 194.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2018-09-11 | September 11, 18 | 2:1 |
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,559.40 | ₹1,259,606,909,400.00 | ₹1,389,990.00 |
| Abbott India Limited | ABBOTINDIA | ₹35,195.00 | ₹747,869,113,500.00 | ₹8,866.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹3,197.00 | ₹541,590,982,000.00 | ₹96,877.00 |
| Gland Pharma Limited | GLAND | ₹2,060.70 | ₹339,512,689,200.00 | ₹140,485.00 |
| Pfizer Limited | PFIZER | ₹5,260.50 | ₹240,655,775,850.00 | ₹16,259.00 |
| Sanofi India Limited | SANOFI | ₹5,881.00 | ₹135,439,430,000.00 | ₹6,018.00 |
| Marksans Pharma Limited | MARKSANS | ₹236.25 | ₹107,059,995,000.00 | ₹3,372,266.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born:
Gender: female
Year Born:
Gender: female
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1977
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about GlaxoSmithKline Pharmaceuticals Limited
The CEO is Bhushan Akshikar.
The current price is ₹3,197.00.
The range is ₹1921-3515.7.
The market capitalization is ₹54,159.10 crores.
The dividend yield is 1.69%.
The P/E ratio is 58.38.
The company operates in the Healthcare sector.
Overview of GlaxoSmithKline Pharmaceuticals Limited (ISIN: INE159A01016) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹54,159.10 crores and an average daily volume of 166,977 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹54.